{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T05:42:55Z","timestamp":1789710175838,"version":"4.0.1"},"reference-count":90,"publisher":"Informa UK Limited","issue":"2","license":[{"start":{"date-parts":[[2019,12,13]],"date-time":"2019-12-13T00:00:00Z","timestamp":1576195200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"consultancy (Bristol-Myers Squibb) and honoraria and research funding"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncol."],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.2217\/fon-2019-0555","type":"journal-article","created":{"date-parts":[[2019,12,13]],"date-time":"2019-12-13T15:35:25Z","timestamp":1576251325000},"page":"4395-4408","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":31,"title":["The role of bosutinib in the treatment of chronic myeloid leukemia"],"prefix":"10.1080","volume":"16","author":[{"given":"Carlo","family":"Gambacorti-Passerini","sequence":"first","affiliation":[{"name":"Department of Medicine & Surgery,University of Milano-Bicocca, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp le","family":"Coutre","sequence":"additional","affiliation":[{"name":"Charit\u00e9\u2013Universit\u00e4tsmedizin Berlin, Corporate member of Freie Universit\u00e4t Berlin, Humboldt-Universit\u00e4t zuBerlin, Germany"},{"name":"Berlin Institute of Health,Department of Hematology, Oncology, and Tumor Immunology, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rocco","family":"Piazza","sequence":"additional","affiliation":[{"name":"Department of Medicine & Surgery,University of Milano-Bicocca, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2019,12,13]]},"reference":[{"key":"e_1_3_3_3_1","unstructured":"National Cancer Institute\n. Cancer Stat Facts: leukemia \u2013 chronic myeloid leukemia (CML). (2018). https:\/\/seer.cancer.gov\/statfacts\/html\/cmyl.html"},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25011"},{"key":"e_1_3_3_5_1","unstructured":"National Comprehensive Cancer Network\n. NCCN Clinical Practice Guidelines in Oncology: chronic myeloid leukemia (2018). www.nccn.org\/professionals\/physician_gls\/pdf\/cml.pdf"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-05-501569"},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(15)00048-4"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwq262"},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.1097\/PPO.0000000000000165"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.75.4663"},{"key":"e_1_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-018-0449-7"},{"key":"e_1_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011573"},{"key":"e_1_3_3_13_1","unstructured":"Novartis\n. Gleevec (imatinib mesylate) prescribing information (2018). www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/021588s053lbl.pdf"},{"key":"e_1_3_3_14_1","unstructured":"European Medicines Agency\n. Summary of product characteristics: imatinib medac (2018) www.ema.europa.eu\/documents\/product-information\/imatinib-medac-epar-product-information_en.pdf"},{"key":"e_1_3_3_15_1","unstructured":"European Medicines Agency\n. Summary of product characteristics: sprycel (dasatinib) (2016). www.ema.europa.eu\/documents\/product-information\/sprycel-epar-product-information_en.pdf"},{"key":"e_1_3_3_16_1","unstructured":"Bristol-Myers Squibb Co\n. Sprycel (dasatinib) prescribing information (2010). www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/021986s7s8lbl.pdf"},{"key":"e_1_3_3_17_1","unstructured":"Novartis\n. Tasigna (nilotinib) prescribing information (2010). www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/022068s004s005lbl.pdf"},{"key":"e_1_3_3_18_1","unstructured":"European Medicines Agency\n. Summary of product characteristics: tasigna (nilotinib) (2019). www.ema.europa.eu\/documents\/product-information\/tasigna-epar-product-information_en.pdf"},{"key":"e_1_3_3_19_1","unstructured":"European Medicines Agency\n. Summary of product characteristics: bosulif (bosutinib) (2018). www.ema.europa.eu\/documents\/product-information\/bosulif-epar-product-information_en.pdf"},{"key":"e_1_3_3_20_1","unstructured":"Pfizer Inc\n. Bosulif (bosutinib) prescribing information (2017). www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/203341s009lbl.pdf"},{"key":"e_1_3_3_21_1","unstructured":"ARIAD Pharmaceuticals\n. Iclusig (ponatinib) prescribing information (2012). www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/203469lbl.pdf"},{"key":"e_1_3_3_22_1","unstructured":"European Medicines Agency\n. Summary of product characteristics: Iclusig (ponatinib) (2019). www.ema.europa.eu\/en\/documents\/product-information\/iclusig-epar-product-information_en.pdf"},{"key":"e_1_3_3_23_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.66.2866"},{"key":"e_1_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djr060"},{"key":"e_1_3_3_25_1","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S19901"},{"key":"e_1_3_3_26_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-06-1199"},{"key":"e_1_3_3_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.334"},{"issue":"2","key":"e_1_3_3_28_1","first-page":"375","article-title":"SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice","volume":"63","author":"Golas JM","year":"2003","unstructured":"Golas JM , ArndtK, EtienneCet al. SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice. Cancer Res.63(2), 375\u2013381 (2003).","journal-title":"Cancer Res."},{"key":"e_1_3_3_29_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0029828"},{"key":"e_1_3_3_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-011-1688-7"},{"key":"e_1_3_3_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-016-0391-6"},{"key":"e_1_3_3_32_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.74.7162"},{"key":"e_1_3_3_33_1","volume-title":"54th Annual Meeting of the American Society of Clinical Oncology (ASCO)","author":"Cortes JE","year":"2018","unstructured":"Cortes JE , MauroMJ, DeiningerMWet al. Bosutinib vs imatinib for newly diagnosed chronic myeloid leukemia in the BFORE trial: 24-month follow-up. In: 54th Annual Meeting of the American Society of Clinical Oncology (ASCO). IL, USA (2018)."},{"key":"e_1_3_3_34_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.7522"},{"key":"e_1_3_3_35_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23788"},{"key":"e_1_3_3_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13108"},{"key":"e_1_3_3_37_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V118.21.1685.1685"},{"key":"e_1_3_3_38_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa022457"},{"key":"e_1_3_3_39_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609324"},{"key":"e_1_3_3_40_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1002315"},{"key":"e_1_3_3_41_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.8899"},{"key":"e_1_3_3_42_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0912614"},{"key":"e_1_3_3_43_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.5"},{"key":"e_1_3_3_44_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.171249"},{"key":"e_1_3_3_45_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24536"},{"key":"e_1_3_3_46_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2016.1174108"},{"key":"e_1_3_3_47_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13801"},{"key":"e_1_3_3_48_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-11-390120"},{"key":"e_1_3_3_49_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-05-355594"},{"key":"e_1_3_3_50_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.7012"},{"key":"e_1_3_3_51_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24423"},{"key":"e_1_3_3_52_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.181"},{"key":"e_1_3_3_53_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-09-739086"},{"key":"e_1_3_3_54_1","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2019.1605239"},{"key":"e_1_3_3_55_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12356"},{"key":"e_1_3_3_56_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/90.11.850"},{"key":"e_1_3_3_57_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V63.4.789.789"},{"key":"e_1_3_3_58_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2017.1379074"},{"key":"e_1_3_3_59_1","first-page":"2432","volume-title":"DeVita, Hellman, and Rosenberg's Cancer: Principles & Practices of Oncology","author":"Gambacorti-Passerinin C","year":"2018","unstructured":"Gambacorti-Passerinin C , le CoutreP. [CML]. In: DeVita, Hellman, and Rosenberg's Cancer: Principles & Practices of Oncology, 11th ed. DeVita VT, LawrenceTS, RosenburgSA (Eds). Wolters Kluwer Health\/Lippincott Williams and Wilkins, PA, USA, 2432 (2018).","edition":"11"},{"key":"e_1_3_3_60_1","doi-asserted-by":"publisher","DOI":"10.1177\/1078155217710553"},{"key":"e_1_3_3_61_1","doi-asserted-by":"publisher","DOI":"10.1586\/17474086.2013.837279"},{"key":"e_1_3_3_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2018.01.004"},{"key":"e_1_3_3_63_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-01-617993"},{"key":"e_1_3_3_64_1","doi-asserted-by":"publisher","DOI":"10.2147\/VHRM.S108874"},{"key":"e_1_3_3_65_1","doi-asserted-by":"publisher","DOI":"10.2147\/JBM.S129821"},{"key":"e_1_3_3_66_1","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2017.1.110"},{"key":"e_1_3_3_67_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.104"},{"key":"e_1_3_3_68_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx219"},{"key":"e_1_3_3_69_1","doi-asserted-by":"publisher","DOI":"10.1111\/imj.13716"},{"key":"e_1_3_3_70_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2017.06.001"},{"key":"e_1_3_3_71_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24360"},{"key":"e_1_3_3_72_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy019"},{"key":"e_1_3_3_73_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-110547"},{"issue":"1","key":"e_1_3_3_74_1","first-page":"42","article-title":"Tyrosine kinase inhibitors for the treatment of chronic-phase chronic myeloid leukemia: long-term patient care and management","volume":"7","author":"Bauer S","year":"2016","unstructured":"Bauer S , BuchananS, RyanI. Tyrosine kinase inhibitors for the treatment of chronic-phase chronic myeloid leukemia: long-term patient care and management. J. Adv. Pract. Oncol.7(1), 42\u201354 (2016).","journal-title":"J. Adv. Pract. Oncol."},{"key":"e_1_3_3_75_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24887"},{"issue":"2","key":"e_1_3_3_76_1","first-page":"160","article-title":"Bosutinib therapy in patients with chronic myeloid leukemia: practical considerations for management of side effects","volume":"7","author":"Ault PS","year":"2016","unstructured":"Ault PS , RoseJ, NodzonLA, KaledES. Bosutinib therapy in patients with chronic myeloid leukemia: practical considerations for management of side effects. J. Adv. Pract. Oncol.7(2), 160\u2013175 (2016).","journal-title":"J. Adv. Pract. Oncol."},{"key":"e_1_3_3_77_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23887"},{"key":"e_1_3_3_78_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-018-0685-2"},{"key":"e_1_3_3_79_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V120.21.2798.2798"},{"issue":"1","key":"e_1_3_3_80_1","first-page":"P148","article-title":"Assessment of early cytogenetic response as a predictor of long-term clinical outcomes in a Phase 1\/2 study of bosutinib in chronic phase CML","volume":"98","author":"Cortes JE","year":"2013","unstructured":"Cortes JE , Br\u00fcmmendorfTH, KhouryHJet al. Assessment of early cytogenetic response as a predictor of long-term clinical outcomes in a Phase 1\/2 study of bosutinib in chronic phase CML. Haematologica.98(Suppl. 1), P148 (2013).","journal-title":"Haematologica."},{"key":"e_1_3_3_81_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-06-511592"},{"key":"e_1_3_3_82_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-06-510396"},{"key":"e_1_3_3_83_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000015222"},{"key":"e_1_3_3_84_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-017-0375-0"},{"key":"e_1_3_3_85_1","doi-asserted-by":"publisher","DOI":"10.18549\/PharmPract.2015.02.559"},{"key":"e_1_3_3_86_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.22019"},{"key":"e_1_3_3_87_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2012.082511"},{"key":"e_1_3_3_88_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-10-309807"},{"key":"e_1_3_3_89_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-017-0958-6"},{"key":"e_1_3_3_90_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-110543"},{"key":"e_1_3_3_91_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.1921.1921"},{"key":"e_1_3_3_92_1","volume-title":"24th congress of the European Hematology Association","author":"Br\u00fcmmendorf TH","year":"2019","unstructured":"Br\u00fcmmendorf TH , GilesF, Gambacorti-PasseriniCet al. Efficacy and safety following dose reduction of bosutinib in previously treated patients with chronic myeloid leukemia: Analysis of the Phase 4 BYOND trial. In: 24th congress of the European Hematology Association. Amsterdam, The Netherlands (2019). https:\/\/library.ehaweb.org\/eha\/2019\/24th\/266215\/tim.h.brmmendorf.efficacy.and.safety.following.dose.reduction.of.bosutinib.in.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D2%2Asearch%3Dtki"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fon-2019-0555","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T06:45:53Z","timestamp":1719125153000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fon-2019-0555"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,13]]},"references-count":90,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["10.2217\/fon-2019-0555"],"URL":"https:\/\/doi.org\/10.2217\/fon-2019-0555","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,13]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2019-09-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-11-15","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-12-13","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}